<DOC>
	<DOCNO>NCT01702415</DOCNO>
	<brief_summary>Null hypothesis : zoledronic acid improve bone density cystic fibrosis . Low bone mineral density ( osteoporosis ) prevalent adult cystic fibrosis ( CF ) ; increase rate bone fracture comparison general population . CF patient start lose bone density adolescence/early adulthood due imbalance bone breakdown formation . Predicted survival patient CF increase 16 year 1970 36.5 year 2009 result increase comorbidities associate increased longevity CF e.g . decrease bone density . Oral intravenous bisphophosphonates know increase bone density CF ; current license oral preparation require daily weekly dosing difficult maintain . Zoledronate , license use , administer intravenously year easier administer . The current evidence relates use disease group e.g . glucocorticoid induce osteoporosis oncology . The purpose study ascertain efficacy cystic fibrosis .</brief_summary>
	<brief_title>Zoledronic Acid Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Diagnosis cystic fibrosis Aged least 18 year Bone mineral density score 1.5 less lumbar spine total hip Able give inform consent Previous solid organ transplant solid organ transplant wait list Long trem oral glucocorticosteroids CRP &gt; 20mg day randomisation Hypocalcaemia Poor dental hygiene</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Bone density</keyword>
</DOC>